Medicare AdvantageCoverageMedium impact
MA08.050c, Alpha-1 Antitrypsin Therapy (e.g., Prolastin-C, Aralast NP, Glassia, Zemaira)
Independence Blue Cross·Pulmonology, Internal Medicine·Medical Policy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
The Alpha-1 Antitrypsin Therapy policy (MA08.050c) covering medications like Prolastin-C, Aralast NP, Glassia, and Zemaira has been reissued for Medicare Advantage plans. This is a policy update affecting coverage and billing for these specialty respiratory medications used to treat Alpha-1 antitrypsin deficiency.
Action Required
Before April 29, 2026: Billing team should review the updated Alpha-1 Antitrypsin Therapy policy at the provided URL to identify any changes in coverage criteria, prior authorization requirements, or billing guidelines for Prolastin-C, Aralast NP, Glassia, and Zemaira. Update billing protocols and prior authorization workflows as needed for Medicare Advantage patients requiring these therapies.